Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer. Nakhlis F, Niman SM, Ueno NT, Troll E, et al. Breast Cancer Res Treat 2023 Dec 28. doi: 10.1007/s10549-023-07195.

Read + Share

Amedeo Smart

Independent Medical Education

Nakhlis F, Niman SM, Ueno NT, Troll E, et al. Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer. Breast Cancer Res Treat 2023 Dec 28. doi: 10.1007/s10549-023-07195.
PMID: 38155272